Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of ALK202 in combination regimens for non-small cell lung cancer
CTR20261872Phase 2Active
- Sponsor
- Allink Biotherapeutics
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ALK202 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Allink Biotherapeutics. Primary endpoints: Dose-limiting toxicity, Treatment-emergent adverse events and 1 more. Started Jul 2026; status: active.
02
Drugs
ALK202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261872.